HK inno.N Entered into an Exclusive License Agreement with mAbxience for Denosumab Biosimilar to Treat Bone Disease
Shots:
- HK inno.N collaborated with mAbxience for a denosumab biosimilar referencing Prolia/Xgeva in the Korean market. The biosimilar will be used to treat and prevent osteoporosis and cancer-related skeletal complications
- Under the terms of the agreement, HK inno.N will obtain the marketing rights for a 60 & 120mg version of the denosumab biosimilars & will apply for domestic approval and proceed with sales. The patent for both drugs is expected to expire in 2025
- Additionally, clinical trials are being conducted by mAbxience to confirm the biosimilars' clinical equivalence to the original denosumab products
Ref: mAbxience | Image: mAbxience
Related News:- mAbxience's MB02 (biosimilar- bevacizumab) Receives EC's Approval for the Treatment of Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
